Medical/Pharmaceuticals

Jolly Good and Teijin Pharma Form a Partnership to Develop VR Digital Therapeutics for Depression

TOKYO, April 23, 2021 /PRNewswire/ -- Jolly Good Inc. ("Jolly Good") and Teijin Pharma Ltd. ("Teijin Pharma") have signed a business partnership agreement to develop VR digital therapeutics ("VR DTx") for Major Depressive Disorder (MDD). Together, they will promote the development of VR DTx for d...

2021-04-23 21:00 2611

Wuxi Strives to Build a World-class Biomedical Industry Chain

WUXI, China, April 22, 2021 /PRNewswire/ -- From April 21 to 23, the 2021 Taihu Bay Future Healthcare Conference was held in Wuxi,China. More than 160 experts including Hejie, Fan Chunhai and many other academicians carried out forward-looking, authoritative, and predictive exchanges and dialogue...

2021-04-22 19:06 968

Seed Health Closes $40 Million in Series A Financing to Launch New Categories, Accelerate Global Distribution and Expand Clinical Research

LOS ANGELES, April 21, 2021 /PRNewswire/ -- Seed Health, a microbial sciences company developing next-generation probiotic applications and live biotherapeutics, today announced the close of a $40 million Series A financing led by impact investor,The Craftory, alongside TechBio investor ARTIS Ven...

2021-04-21 20:00 2734

111 to Announce First Quarter 2021 Unaudited Financial Results on May 19, 2021 - Conference Call to Follow

SHANGHAI, April 21, 2021 /PRNewswire/ – 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results...

2021-04-21 20:00 2094

Samsung Biologics Celebrates Its 10th Anniversary with Its Mission, "Driven. For Life."

INCHEON, South Korea, April 21, 2021 /PRNewswire/ -- Samsung Biologics, the world's leading contract development and manufacturing organization, celebrated the 10th anniversary of its founding today at its global headquarters in Songdo, Incheon via a virtual ceremony.

2021-04-21 19:00 1339

China Biologic Announces Completion of Going Private Transaction

BEIJING, April 20, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced the completion of its merger (the "Merger") with CBPO Group Limited ("Merger...

2021-04-21 04:30 4525

Transcenta Received IND Clearance from US FDA for Initiating Phase I Clinical Trial for its Bi-functional Anti-PD-L1/TGF-β Antibody TST005

SUZHOU, China, April 20, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance of i...

2021-04-20 20:54 1021

AACR 2021-ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration

SHENZHEN, China, April 19, 2021 /PRNewswire/ -- On April 15, 2021, ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration through publication in a virtual poster at the AACR annual meeting. MVR-T3011 is a replication competent and genetically modified oncolyti...

2021-04-20 08:30 1486

Terumo Blood and Cell Technologies and CSL Plasma Announce Collaboration to Deliver New Plasma Collection Platform

LAKEWOOD, Colo. and BOCA RATON, Fla., April 19, 2021 /PRNewswire/ -- Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial of the investigational plasmapheresis device ...

2021-04-20 05:00 2128

China Pharma Expects Considerable Increase in Growth Opportunities Related to Hainan Free Trade Port

HAIKOU, China, April 19, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, commented on the policy statements in "Several Special Measures to Support the Construction of Hainan Free Trade Port to Rel...

2021-04-19 20:30 2875

CNPharm has succeeded in maintaining IC100 for 24 hours with one injection

- Trail-blazing diversification of the repurposing of Niclosamide - Full-scale clinical preparation of injections for severely ill patients SEOUL, South Korea, April 19, 2021 /PRNewswire/ -- Hyundai Bioscience (Symbol 048410), a KOSDAQ listed company, announced on the 19th that its major sharehol...

2021-04-19 20:15 1402

Porton Biologics Announces Closing Series-A Financing to Drive Commercial Production of Gene and Cell Therapy

SUZHOU, China, April 19, 2021 /PRNewswire/ -- On April 16, 2021, Suzhou Porton BiologicsLtd. (hereinafter referred to as Porton Biologics), a subsidiary of Porton Pharma Solutions Ltd. (hereinafter referred to as Porton Pharma Solutions) (300363.SZ), which focuses on gene and cell therapy CDMO se...

2021-04-19 20:00 4283

PharmAbcine announces Clinical Trial Collaboration with MSD for the Phase II study in mTNBC

DAEJEON, South Korea, April 19, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has entered into an agreement with MSD to initiate a Phase II combination trial of olin...

2021-04-19 20:00 1332

Transcenta Announced Successful First Patient Dosed in Phase I Clinical Study of TST001 Combined with CAPOX for the Treatment of Patients with First-line Locally Advanced Unresectable or Metastatic Gastric Cancer

SUZHOU, China, April 18, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the first patient has been success...

2021-04-19 08:00 1627

Kintor Pharmaceuticals Announced Successful Dosing of the First Batch of Patients for Acne Vulgaris Phase I/II Clinical Trial of Pyrilutamide

SUZHOU, China, April 16, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced today the clinical trial of Pyrilutamide as a treatment for the acne vulgaris has completed the first b...

2021-04-16 18:29 5064

Transcenta Announced Presentation of Preclinical Data of TST005 at 2021 AACR Virtual Annual Meeting

SUZHOU, China, April 15, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, presented preclinical data of TST005, a bi-functio...

2021-04-16 08:00 1203

Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China

SUZHOU, China, April 15, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical" or the "Company"), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that it has received approval from t...

2021-04-15 18:20 4745

Adlai Nortye Announces First Patient Dosed in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

HANGZHOU, China, April 14, 2021 /PRNewswire/ -- Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the global phase III clinical trial (BURAN) at Shanghai Eastern Hospital Medical Center inChin...

2021-04-15 09:00 2109

Kintor Pharmaceutical and Visum Announced Strategic Partnership to Expand Proxalutamide Manufacturing

SUZHOU, China, April 14, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical" or the "Company"), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, recently announced a strategic partnership with Hain...

2021-04-14 22:18 5113

Molecular Matrix and GenScript Partner to Launch SARS-CoV-2 Neutralizing Antibody Testing Service for Public

PISCATAWAY, New Jersey and WEST SACRAMENTO, Calif., April 13, 2021 /PRNewswire/ --Molecular Matrix, Inc.  (MMI) and GenScript Biotech Corp . announced today that they have partnered to offer GenScript's SARS-CoV-2 neutralizing antibody t...

2021-04-13 19:30 1467
1 ... 148149150151152153154 ... 197